Hakim CHKS, Perez-LopezDO, WasalaNB, et al.Cas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystophic canine models. Nat Commun, 2021; 12:6769.
2.
CharlesworthCT, DeshpandePS, DeverDP, et al.Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nat Med, 2019; 25:249–254.
3.
WagnerDL, AminiL, WenderingDJ, et al.High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population. Nat Med, 2019; 25:242–248.
4.
FerdosiSR, EwaishaR, MoghadamF, et al.Multifunctional CRISPR-Cas9 with engineered immunosilenced human T cell epitopes. Nat Commun, 2019; 10:1842.
5.
LiA, TannerMR, LeeCM, et al.AAV-CRISPR gene editing is negated by pre-existing immunity to Cas9. Mol Ther, 2020; 28:1432–1441.
6.
NelsonCE, WuY, GemberlingMP, et al.Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy. Nat Med, 2019; 25:427–432.
7.
ChewWL, TabebordbarM, ChengJK, et al.A multifunctional AAV-CRISPR-Cas9 and its host response. Nat Methods, 2016; 13:868–874.
8.
MorenoAM, PalmerN, AlemanF, et al.Immune-orthogonal orthologues of AAV capsids and of Cas9 circumvent the immune response to the administration of gene therapy. Nat Biomed Eng, 2019; 3:806–816.
9.
ThakorePI, KwonJB, NelsonCE, et al.RNA-guided transcriptional silencing in vivo with S. aureus CRISPR-Cas9 repressors. Nat Commun, 2018; 9:1674.
10.
MendellJR, CampbellK, Rodino-KlapacL, et al.Dystrophin immunity in Duchenne's muscular dystrophy. N Engl J Med, 2010; 363:1429–1437.
11.
CalcedoR, SomanathanS, QinQ, et al.Class I-restricted T-cell responses to a polymorphic peptide in a gene therapy clinical trial for alpha-1-antitrypsin deficiency. Proc Natl Acad Sci U S A, 2017; 114:1655–1659.
12.
MuellerC, GernouxG, GruntmanAM, et al.5 Year expression and neutrophil defect repair after gene therapy in alpha-1 antitrypsin deficiency. Mol Ther, 2017; 25:1387–1394.
13.
FlotteTR, TrapnellBC, HumphriesM, et al.Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing alpha1-antitrypsin: interim results. Hum Gene Ther, 2011; 22:1239–1247.
14.
BrantlyML, SpencerLT, HumphriesM, et al.Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alphal-antitrypsin (AAT) vector in AAT-deficient adults. Hum Gene Ther, 2006; 17:1177–1186.
15.
GernouxG, WilsonJM, MuellerC. Regulatory and exhausted T Cell responses to AAV capsid. Hum Gene Ther, 2017; 28:338–349.
FerreiraV, PetryH, SalmonF. Immune responses to AAV-vectors, the Glybera example from bench to bedside. Front Immunol, 2014; 5:82.
18.
FerreiraV, TwiskJ, KwikkersK, et al.Immune responses to intramuscular administration of alipogene tiparvovec (AAV1-LPL(S447X)) in a phase II clinical trial of lipoprotein lipase deficiency gene therapy. Hum Gene Ther, 2014; 25:180–188.
19.
CarpentierAC, FrischF, LabbeSM, et al.Effect of alipogene tiparvovec (AAV1-LPL(S447X)) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients. J Clin Endocrinol Metab, 2012; 97:1635–1644.
20.
FlaniganKM, CampbellK, ViolletL, et al.Anti-dystrophin T cell responses in Duchenne muscular dystrophy: prevalence and a glucocorticoid treatment effect. Hum Gene Ther, 2013; 24:797–806.
21.
BoisgeraultF, MingozziF. The skeletal muscle environment and its role in immunity and tolerance to AAV vector-mediated gene transfer. Curr Gene Ther, 2015; 15:381–394.
22.
MendellJR, Al-ZaidyS, ShellR, et al.Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. N Engl J Med, 2017; 377:1713–1722.
23.
RussellS, BennettJ, WellmanJA, et al.Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet, 2017; 390:849–860.
24.
CortiM, ElderM, FalkD, et al.B-cell depletion is protective against anti-AAV capsid immune response: a human subject case study. Mol Ther Methods Clin Dev, 2014; 1.
25.
CortiM, LiberatiC, SmithBK, et al.Safety of intradiaphragmatic delivery of adeno-associated virus-mediated alpha-glucosidase (rAAV1-CMV-hGAA) gene therapy in children affected by Pompe disease. Hum Gene Ther Clin Dev, 2017; 28:208–218.
26.
CortiM, CleaverB, ClementN, et al.Evaluation of readministration of a recombinant adeno-associated virus vector expressing acid alpha-glucosidase in pompe disease: preclinical to clinical planning. Hum Gene Ther Clin Dev, 2015; 26:185–193.
27.
UnzuC, Hervas-StubbsS, SampedroA, et al.Transient and intensive pharmacological immunosuppression fails to improve AAV-based liver gene transfer in non-human primates. J Transl Med, 2012; 10:122.
28.
DelgoffeGM, KoleTP, ZhengY, et al.The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity, 2009; 30:832–844.
29.
ZeiserR, Leveson-GowerDB, ZambrickiEA, et al.Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. Blood, 2008; 111:453–462.
30.
BiswasM, KumarSRP, TerhorstC, et al.Gene therapy with regulatory T cells: a beneficial alliance. Front Immunol, 2018; 9:554.
31.
ArjomandnejadM, SylviaK, BlackwoodM, et al.Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells. Mol Ther Methods Clin Dev, 2021; 23:490–506.
32.
WagnerDL, PeterL, Schmueck-HenneresseM. Cas9-directed immune tolerance in humans-a model to evaluate regulatory T cells in gene therapy?. Gene Ther, 2021; 28:549–559.
